MDMA-assisted psychotherapy

MDMA-assisted psychotherapy (MDMA-AT) is the use of prescribed doses of MDMA as an adjunct to psychotherapy sessions. Research suggests that MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), including complex PTSD (C-PTSD), might improve treatment effectiveness. In 2017, a Phase II clinical trial led to a breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for potential use as a treatment for PTSD.

MDMA-assisted psychotherapy is currently under investigation as a treatment for various other mental health disorders, including major depressive disorder, social anxiety in people with autism, alcohol use disorder, and mood disturbances in individuals facing life-threatening illnesses. The research is controversial in part because recreational MDMA use has been associated with harmful effects among some users.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.